India, June 26 -- Axosome Therapeutics Inc. (AXSM), a biopharmaceutical company, on Friday announced the dosing of the first patient in the Phase 3 FOCUS-3 trial for Solriamfetol in treating adolescents with attention deficit/hyperactivity disorder.
Attention deficit/hyperactivity disorder (ADHD) is a chronic neurobiological and developmental disorder characterized by a persistent pattern of inattention, hyperactivity, or impulsivity, that interferes with functioning or development. Approximately 7 million children in the U.S. alone have been diagnosed with the disorder.
Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist, and 5-HT1A agonist being developed for the treatment of attention deficit hyperact...